PARIS & BOSTON, September 19, 2023--Regulatory News: Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext Growth: ALMKT) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, announces that Jeong Kim, M.D., and the Endoscopy Institute of Hawaii (EIH) clinical team have completed more than 1,200 Cellvizio procedures for the diagnosis and interventional treatment of gastric disease, a condition which can lead to gastric cancer.
PARIS, September 06, 2023--Regulatory News: Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY):
PARIS & BOSTON, August 04, 2023--Regulatory News: Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, announces that the transfer of its ordinary shares from the Euronext Paris regulated market (compartment C) to the Euronext Growth Paris multilateral trading facility will be effective on August 8, 2023.